Protein-ligand titrations can readily be monitored with a trimethylsilyl (TMS) tag. Owing to the intensity, narrow line shape and unique chemical shift of a TMS group, dissociation constants can be determined from straightforward 1D 1 H-NMR spectra not only in the fast but also in the slow exchange limit. The tag is easily attached to cysteine residues and a sensitive reporter of ligand binding also at sites where it does not interfere with ligand binding or catalytic efficiency of the target protein. Its utility is demonstrated for the Zika virus NS2B-NS3 protease and the human prolyl isomerase FK506 binding protein.
Introduction
Drug discovery critically depends on the identification of suitable lead compounds among the vast pool of candidates evaluated during extensive screening or elaboration campaigns. Specificity of binding and binding affinity to the drug target are two essential parameters defining a lead compound. Nuclear magnetic resonance (NMR) spectroscopy is uniquely positioned to assess both parameters simultaneously and, consequently, has become an important tool in the pharmaceutical industries to screen, identify and validate small molecules as potential lead candidates (Gossert and Jahnke 2016) . In recent years, NMR spectroscopy has gained particular importance in the early stages of the drug discovery process, where fragmentbased lead discovery has proven an efficient approach to identify small ligands that bind to the target biomolecule (Doak et al. 2016) . In this context, the main focus is often on weakly binding ligand molecules that are in rapid exchange between bound and free state. In subsequent stages of the drug discovery process, however, alternative methods are necessary to analyze the binding epitope and determine the affinity of elaborated ligands, which are usually in slow chemical exchange on the NMR time scale (Nitsche and Otting 2018) .
Although 2D NMR spectra with uniformly 15 N-labeled target proteins are considered to be the NMR 'gold standard' to assess ligand binding in both early and later stages of the drug discovery process, several alternative strategies have been developed that do not rely on expensive isotope labeling and require significantly smaller protein quantities. A prominent example is the use of 1D 19 F-NMR spectroscopy to detect fluorine-substituted tryptophan, trifluoromethoxy-L-phenylalanine, or cysteine residues, that were post-translationally furnished with a CF3 group, in the target protein (Jackson et al. 2007; Cellitti et al. 2008; Arntson and Pomerantz 2016; Liu et al. 2012) . The large chemical shift anisotropy associated with 19 F spins imparts high sensitivity towards changes in the environment but is also a source of line broadening. 1 H-NMR spectra offer intrinsically higher sensitivity and, in practice, most NMR spectrometers are equipped for 1 H-NMR but not always for 19 F-NMR spectroscopy. The greater sensitivity of 1 H-NMR spectra, however, comes at the expense of spectral overlap between protein and ligand signals, which makes it harder to quantify the protein-ligand interactions from 1D NMR spectra. To a large extent, this problem can be alleviated by labels with a tertiary butyl (tBu) group that produces an exceptionally narrow and intense NMR signal arising from nine methyl protons with degenerate chemical shift. This often makes it possible to assign and track tBu signals in the presence of modest spectral overlap with protein signals. Recent examples have demonstrated this for ligands containing a tBu group and proteins containing a siteselectively incorporated tBu-tyrosine residue (Chen et al. 2015; Chen et al. 2016; Jabar et al. 2017) . When the spectral overlap is pronounced, however, the 1 H-NMR signal even of a tBu group may be difficult to identify and track. Even more limiting, spectral overlap prevents accurate integration of the tBu resonance, compromising quantitative evaluation of any titration experiments, where the ligand is in slow exchange between bound and free state.
Here we present a strategy that relies on the unique 1 H chemical shift of a trimethylsilyl (TMS) group near 0 ppm, where spectral overlap with protein signals is much less severe than at the chemical shift of a tBu group (which is at about 1.3 ppm). Previously, we investigated the possibility of site-specific incorporation of p-TMS-phenylalanine (TMSf) by genetic encoding but, due to ring currents, the TMS signal appeared at about 0.3 rather than 0 ppm and the amino acid could not be incorporated in high yield (Loh et al. 2018 ). Furthermore, the signal proved to be prone to extreme line broadening, when a target protein containing TMSf was titrated with a low molecular weight ligand, which may be attributed to the overall rigidity of the TMSf amino acid. To alleviate these drawbacks, we designed a tag that is identical to the TMS tag 1 ( Figure   1 ) except that it contains an amide rather than an ester group. Following attachment to a single cysteine residue in the E. coli single-stranded DNA binding protein, the amide tag enabled the observation of intermolecular nuclear Overhauser effects (NOEs) with single-stranded DNA (Jabar et al. 2017) . In other proteins, however, the tag proved prone to peak doubling, which could be attributed to cis/trans amide bond isomerization.
The new TMS tag 1 (Figure 1 ) solves this problem by containing a more flexible ester moiety. It can be selectively attached to solvent-exposed cysteine residues by generating a redoxstable thioether bond between tag and protein. It produces a single TMS signal at a chemical shift near 0 ppm. Its 1 H-NMR signal is easy to detect and, owing to its chemical shift in a spectral region with few protein peaks, its intensity can readily be quantified. This makes the tag ideal for monitoring ligand binding events both in the fast and slow exchange regimes with small quantities of protein and ligand. We demonstrate the approach for two different drug targets, the Zika virus NS2B-NS3 protease (ZiPro) and the human prolyl isomerase FK506 binding protein (FKBP). ZiPro is closely related to the NS2B-NS3 proteases of a range of flaviviruses such as dengue and West Nile viruses, which cause regular epidemic outbreaks (Boldescu et al. 2017 ).
The NS2B-NS3 proteases catalyze the post-translational processing of the viral precursor polyprotein into smaller protein units, which are essential for viral replication (Nitsche et al. 2014 ). Based on previous successes with HIV and HCV protease inhibitors, flaviviral proteases are promising drug targets, but drug development has been frustrated by the polar character of substrate-derived inhibitors, a shallow substrate binding site, and a lack of structural elucidation, and only few inhibitors have been identified for ZiPro (Boldescu et al. 2017; Nitsche et al. 2014 ).
Human FKBP is the target of the immunosuppressive drugs tacrolimus (FK-506) and rapamycin, which suppress organ rejection after allogeneic transplantations (Siekierka et al. 1989 ). FKBPs are involved in multiple regulatory pathways, offering prospects for prevention and treatment of a broad range of diseases (Bonner and Boulianne 2017) .
Materials and Methods

Synthesis of the trimethylsilyl tag
Details of the protocol for the chemical synthesis of the trimethylsilyl tag 1 (Figure 1 ) are given in the Supporting Information.
Preparation of the wild type and V36C mutant of the Zika virus NS2B-NS3 protease
The construct of the Zika virus NS2B-NS3 protease (ZiPro) has been described previously Nitsche et al. 2017) . Briefly, it includes 48 hydrophilic core residues of NS2B (residues 48*-95*, where the star indicates residues in NS2B) followed by a Gly4SerGly4 linker, the N-terminal residues of the NS3 protease domain (residues 1-170), and a His6 tag. The mutations R95*A, K15N, R29G, C80S and C143S were introduced to increase stability, reduce the potential of auto-cleavage, and avoid dimerization (Lei et al. 2016; Mahawaththa et al. 2017; Nitsche et al. 2017 ). This construct is referred to as wild type. The mutation V36C was introduced for selective ligation of compound 1 to position 36. The expression construct used the T7 expression vector pETMCSI (Neylon et al. 2000) . The plasmid was transformed into E. coli BL21(DE3) and cells were grown in LB medium containing ampicillin at 37 °C until an OD600 value of 0.5-0.8 was reached. Subsequently, overexpression was induced with IPTG (1 mM) and the cells were incubated overnight at room temperature. The cells were pelleted by centrifuging at 5000 g for 10 minutes and lysed by passing twice through a French Press (SLM Aminco, USA) at 830 bars. The cell lysate was centrifuged for 1 h at 34,000 g and the supernatant was loaded onto a 5 ml Ni-NTA column (GE Healthcare, USA) pre-equilibrated with loading buffer (50 mM Tris-HCl, pH 7.5, 300 mM NaCl, 10% glycerol).
The protein was eluted with a gradually increasing concentration of elution buffer (50 mM Tris-HCl, pH 7.5, 300 mM NaCl, 300 mM imidazole, 10% glycerol), fractions were analyzed by 12% SDS-PAGE, and the buffer was exchanged to 20 mM MES, pH 6.5, 150 mM NaCl.
Preparation of FKBP R18C
A construct of the human prolyl isomerase FK506 binding protein (FKBP) with C-terminal His6 tag was incorporated into a pCDF-1b vector (Novagen) using the restriction sites NcoI and NotI.
The additional mutations C22S and R18C were introduced for site-selective tagging of position 18 with compound 1. The plasmid was transformed into E. coli BL21(DE3) and cells were grown in LB medium containing streptomycin at 37 °C until an OD600 value of 0.5-0.8 was reached. Overexpression was induced with IPTG (1 mM) and the cells were incubated overnight at room temperature. The cells were pelleted by centrifuging at 5000 g for 10 minutes and lysed by passing twice through a French Press at 830 bars. The cell lysate was centrifuged for 1 h at 34,000 g and the supernatant was loaded onto a 5 ml Ni-NTA column (GE Healthcare, USA) pre-equilibrated with loading buffer (50 mM Tris-HCl, pH 7.5, 300 mM NaCl, 10% glycerol, 5 mM 2-mercaptoethanol). The protein was eluted with a gradually increasing concentration of elution buffer (50 mM Tris-HCl, pH 7.5, 300 mM NaCl, 300 mM imidazole, 10% glycerol, 5 mM 2-mercaptoethanol) and fractions were analyzed by 12% SDS-PAGE. The buffer was exchanged to buffer A (50 mM sodium phosphate buffer, pH 6.5, 150 mM NaCl, 5 mM 2mercaptoethanol), and the protein was loaded onto a GE Superdex 75 (HiLoad 16/60) size exclusion column and eluted with buffer A.
Tagging procedure
ZiPro V36C and FKBP R18C samples were treated with DTT (2 mM) for 1 h at room temperature, before the buffer was exchanged to buffer A (20 mM MES, pH 6.5, 150 mM NaCl, 10% glycerol). 100 µM samples were subsequently incubated with compound 1 (500 µM, 10 mM DMSO stock) overnight at room temperature. The buffer was changed to NMR buffer (20 mM MES, pH 6.5, 150 mM NaCl, 10% D2O).
NMR measurements and Kd determination
All protein NMR spectra were recorded in 3 mm NMR tubes at 25 °C, using an 800 MHz Bruker Avance III NMR spectrometer equipped with a 5 mm TCI cryoprobe. Each titration step added ligand from a concentrated DMSO stock and a 1 H-NMR spectrum was recorded with water suppression by the double spin-echo sequence (Hwang and Shaka 1995) , using 512 scans per spectrum with a recovery delay of 1.3 seconds. The spectra were calibrated with respect to the water frequency. A control experiment with DMSO alone added at the concentration of the final titration point confirmed that solvent-induced chemical shift changes were insignificant. In the case of fast chemical exchange (FKBP), the dissociation constant was determined from the change in chemical shift of the TMS signal observed during titration with ligand. In the case of slow chemical exchange (ZiPro), the dissociation constant was determined from the change in relative peak intensities of the TMS signal of the complex, where the peak height of the TMS peak was divided by the overall integral of the spectral region between 0.5 and 0.9 ppm.
Results and Discussion
Tag synthesis and tagging reaction
The TMS tag 1 was readily synthesized in large quantities via only two synthetic steps (Scheme S1). The purity of the synthesized compounds was ≥ 95%. Quantitative and selective alkylation of single cysteine residues in the target proteins was achieved at neutral pH without any additional reagents, except that the TMS tag was added dissolved in DMSO.
Zika virus NS2B-NS3 protease
To study inhibitor binding at the active site of ZiPro, we installed the TMS group close to the catalytic center formed by Ser135, His51, and Asp75 (Figure 2 ). Visual inspection of the crystal structure of ZiPro (PDB code: 5LC0) (Lei et al. 2016) suggested Val36 as a suitable residue for tagging, which was consequently mutated to cysteine. To avoid cross-reactivity with the solvent-exposed residues Cys80 and Cys143 in the wild-type amino-acid sequence, these residues were mutated to serine residues as in previous studies of ZiPro (Lei et al. 2016; Mahawaththa et al. 2017; Nitsche et al. 2017 ). These mutations were present in all ZiPro constructs used in this work and we refer, in the following, to the double-mutant C80S/C143S as wild type and the triple-mutant V36C/C80S/C143S as ZiPro V36C. Reduced ZiPro V36C readily reacted with the TMS tag 1 as confirmed by high-resolution mass spectrometry ( Figure S2 ). Figure 2 illustrates the attachment site of 1 relative to the active site of ZiPro. The high solvent exposure of 1 entails high flexibility of the tag, which supports a narrow line shape of its TMS signal in the 1 H-NMR spectrum and, therefore, high sensitivity.
To confirm that the installation of a TMS tag adjacent to the active site has no significant influence on substrate binding and enzymatic reactivity, we compared the kinetic parameters Km and kcat of the tagged mutant with wild-type ZiPro (Table 1, Figure S1 ). Both proteins displayed similar Km values, indicating unencumbered substrate binding. Equally, the kcat values were only marginally different, with a slight kcat increase for the tagged protease compared to the wild type, and the overall catalytic efficiencies (kcat/Km) were indistinguishable. This indicates that the presence of the tag presents no significant perturbation. The 1 H-NMR spectrum of tagged ZiPro only showed a single narrow TMS peak at about 0.06 ppm (Figure 3) as expected for a homogeneous sample, which was subsequently used for titration with the ligand 2.
Compound 2, which is known as an active-site inhibitor of flaviviral proteases (de la Cruz et al. 2011; Nitsche et al. 2014; Brecher et al. 2017) , was chosen as a model ligand to assess the performance of the TMS tag 1 in a ligand titration experiment. Inhibition experiments revealed IC50 values of about 160 µM for the wild type and the tagged mutant V36C (Table 1) .
This value is two orders of magnitude higher than reported previously (Lim et al. 2016) , but the similarities of the IC50 values determined under identical conditions for the tagged and wild type versions ( Table 1 ) clearly indicate that the TMS tag at position 36 does not influence the intermolecular recognition and binding interaction.
Titration of tagged ZiPro V36C with compound 2 led to the appearance of a new TMS peak for the complex while the original TMS peak of the free protein weakened and disappeared ( Figure 3) , showing that the ligand exchanges slowly on the NMR time scale in agreement with previous observations . A second, smaller TMS peak appearing further up-field was attributed to a complex with the hydrolysis products of compound 2, which is prone to hydrolysis in aqueous solution and proteolytic cleavage by proteases. Hydrolysis of 2 was detected by the gradual emergence of the characteristic yellow color of p-nitrophenolate during the titration. An additional smaller TMS peak was not observed in the titration experiments with FKBP, indicating that the ester bond of the TMS tag is stable. After 24 h at 25 o C, however, the FKBP sample displayed two additional small TMS signals with integrals less than 10% of the main peak, which may be attributed either to partial hydrolysis of the tag or protein degradation.
Determining the Kd value in situations of slow exchange is difficult, as it requires low protein concentrations in the vicinity of the dissociation constant. This presents a problem, as the low sensitivity of NMR spectroscopy demands relatively high sample concentrations. The high sensitivity afforded by the 1 H-NMR signal of the TMS group thus presents a clear advantage.
For example, 1D NMR spectra of a 75 µM solution of tagged ZiPro provided excellent signal-tonoise ratios already within a few minutes. In view of the IC50 values, we expected a dissociation constant Kd in the two-to three-digit micromolar range. In the slow exchange regime, the Kd value can be determined using where I denotes the TMS peak intensity of the complex and Imax the TMS peak intensity observed for the fully saturated complex, and [L] and [P] are the concentrations of ligand and protein, respectively. As the intensity of only a single TMS peak is monitored, the approach is independent of its T1 and T2 relaxation times, so long as excess ligand does not modify the properties of the complex. Apparent peak intensities can vary, however, if the NMR sample is removed from the magnet and re-inserted for each titration step. Therefore, it proved important to reference the intensity of the TMS peak to an internal standard. While, in principle, the integral of the TMS peak of the complex could be compared with the sum of the integrals of the TMS signals of the complex and free protein, more reliable measurements were obtained by normalizing the peak height of the TMS peak of the complex (measured with local baseline correction to establish the base of the peak) by the overall integral of the methyl region of the NMR spectrum (0.5-0.9 ppm). Figure 4 shows the fit of the NMR titration data to equation (1), revealing a Kd value of 64 ± 27 µM for compound 2.
FKBP
To validate the utility of the tag for a different protein-ligand complex, we investigated FKBP as a second model system with two different ligands (3 and 4) , which are weakly and tightly binding inhibitors. For site-specific tagging of FKBP with compound 1 adjacent to the binding site of inhibitor 3, the natural cysteine residue in position 22 was mutated to serine and the solvent-exposed residue Arg18 was mutated to cysteine for tagging ( Figure 5 ). FKBP R18C was readily and selectively tagged with compound 1, as confirmed by mass spectrometry (Figure S3) .
In contrast to the experiments conducted with ZiPro and ligand 2, ligand 3 was stable during the experiment and the TMS signal shifted gradually with increasing ligand concentration, maintaining a single peak throughout the titration experiment ( Figure 6 ). Compound 3 has previously been identified as low-molecular weight ligand for FKBP by 2D NMR methods, where residues in the binding site highlighted in Figure 5 displayed the characteristics of fast chemical exchange (Shuker et al. 1996) . Our data confirm the fast exchange situation and allow determination of the Kd value from simple 1D NMR spectra (Figure 7) .
The dissociation constant of the complex of FKBP with compound 3 has been reported previously as 0.1 mM (Shuker et al. 1996) . To determine the Kd value, the titration curve of Figure 7 determined a Kd value of 94 ± 10 µM, which is in excellent agreement with the value reported previously (Shuker et al. 1996 ).
Finally, we tested the TMS tag for its capability to monitor binding events remote from the tagging site. We chose the drug rapamycin (4), which binds to FKBP with very high affinity (Ki = 0.2 nM) at a site far from the TMS tag ( Figure 5) (Bierer et al. 1990) . Dissociation constants in the subnanomolar concentration range cannot be determined by conventional NMR experiments. The actual binding event, however, was very clearly detected by the TMS signal ( Figure 8 ). The tag thus offers a sensitive probe not only for Kd determinations, but also for the detection of binding events between large biomolecules without a requirement of immediate proximity to the binding interface.
Concluding remarks
The binding affinity is a very important validation parameter for any further development of lead candidates in drug discovery. Quite generally, using NMR to monitor the target protein during titration experiments has the great advantage of reporting not only on ligand binding but also the continued integrity of the protein towards aggregation and unfolding. NMR spectroscopy of uniformly isotope-labeled proteins thus is routinely used to detect binding and measure dissociation constants, but this is difficult for very large proteins and proteins that cannot easily be enriched with stable isotopes. The chemical tag presented here capitalizes on the chemical shift of the TMS group in a spectral region that contains few 1 H-NMR signals of the protein and therefore enables accurate measurement of peak intensities. It is easy to use, detects binding with high sensitivity, and allows the quantitative measurement of dissociation constants not only in the fast but also the slow exchange regime. In the slow exchange limit, it is necessary to quantify the peak intensity and this is difficult when the peak is not in a spectral region with minimal signal overlap, as the protein spectrum changes step-wise in response to added ligand and therefore the baseline may not always be easy to identify. We anticipate that the simplicity of the tag, tagging reaction, and NMR detection will make the TMS tag 1 popular in different stages of the drug discovery process for proteins containing a single reactive cysteine residue. Work is in progress to broaden the approach by genetic encoding of an unnatural amino acid containing a TMS group with a chemical shift near 0 ppm. Austrian Science Fund (FWF) (DK Molecular Enzymology W901 to K.Z.) and by NAWI Graz is gratefully acknowledged. Errors were calculated with respect to signal-to-noise ratios. MHz NMR spectrometer. The gradual change in the chemical shift of the TMS peak was used to calculate the binding affinity (Figure 7) . The titration ratios of protein to ligand are indicated. 
